Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system

Brain Research

Volumn 773, Issue 1-2, 1997, Pages 108-116

  Koshimura, Isao ^a   Imai, Hisamasa ^a   Hidano, Toyoko ^a   Endo, Kiyonori ^a   Mochizuki, Hideki ^a   Kondo, Tomoyoshi ^a   Mizuno, Yoshikuni ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3,4 Dimethoxyphenylethylamine; Dopamine; MPP+; Osmotic pump; Parkinson's disease; Tetrahydroisoquinoline; Tetrahydropapaverine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVERATRYLAMINE; TETRAHYDROPAPAVERINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME ANALYSIS; HISTOCHEMISTRY; MALE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PUTAMEN; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CAUDATE NUCLEUS; CORPUS STRIATUM; DIMETHOXYPHENYLETHYLAMINE; DOPAMINE; ISOQUINOLINES; MALE; NEUROTOXINS; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 0030726396     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00922-0     Document Type: Article

References (62)

1. Barbeau A., De Groot J.A., Tremblay D.R., Donaldson J. Urinary excretion of a 3,4-dimethoxypheniylethylamine like substance in Parkinson's disease. Rev. Can. Biol. 22:1963;469-472.
2. Barbeau A., Lescop J., Duplessis P., Elie R. Effect of 3,4-dimethoxyphenylethylamine injections upon dopamine metabolism in rats and dogs. Experientia. 23:1967;536-538.
3. Barbeau A., Singh P., Gaudreau P., Jouert M. Effect of 3,4-dimethoxyphenylethylamine injections on concentration of catecholamines in the rat brain. Rev. Can. Biol. 24:1965;229-232.
4. Barbeau A., Singh P., Joubert M. Effect of 3,4-dimethoxyphenylethylamine injections on catecholamine metabolism in the rat and monkeys. Life Sci. 5:1966;757-767.
5. Barbeau A., Tetreault L., Oliva L., Morazain L., Cardin L. Pharmacology of akinesia; investigation on 3,4-dimethoxyphenylethylamine. Nature. 209:1966;719-721.
6. Calne D.B., Langston J.W. Aetiology of Parkinson's disease. Lancet. ii:1983;1457-1459.
7. +) decrease dopamine and increase acetylcholine in the mouse neostriatum. Neuropharmacology. 24:1985;585-586.
8. Chiba K., Trevor A.J., Castagnoli N.J. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
9. +, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 128:1985;1228-1232.
10. Collins M.A., Neafsey E.J. Beta-carboline analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci. Lett. 55:1985;179-184.
11. Collins M.A., Neafsey E.J., Matsubara K., Cobuzzi R.J., Rollema H. Indole-N-methylated β-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res. 570:1992;154-160.
12. D'Amato R.J., Lipman Z.P., Snyder S.H. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science. 231:1986;987-989.
13. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 109:1979;249-254.
14. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
15. Ernst A.M. Phenomena of hypokinetic rigid type caused by O-methylation of dopamine in the para-position. Nature. 193:1962;178-179.
16. Friedhoff A.J., Van Winkle E. The characteristic of an amine found in the urine of schizophrenic patients. J. Nerv. Ment. Dis. 135:1962;550-555.
17. Friedhoff A.J., Van Winkle E. Isolation and characterization of a compound from the urine of schizophrenics. Nature. 194:1962;897-898.
18. Good P.F., Olanow C.W., Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593:1992;343-346.
19. Goto K., Mochizuki H., Hattori T., Nakamura N., MIzuno Y. Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture. Brain Res. 754:1977;260-268.
20. Hattori N., Tanaka M., Ozawa T., Mizuno Y. Immunohistochemical studies on Complex I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30:1991;563-571.
21. Imai H., Nakamura T., Endo K., Narabayashi H. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology. Brain Res. 474:1988;327-332.
22. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
23. Jenner P., Dexter D.T., Sian J., Schapira A.H.V., Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32:1992;S82-S87.
24. Johannessen J.N., Chiueh C.C. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36:1985;219-224.
25. Kuehl F.A., Hichens M., Ormond R.E., Meisinger M.A.P., Gale P.H., Cirillo V.J., Brinc N.G. Para-O-methylation of dopamine in schizophrenic and normal individuals. Nature. 4941:1964;154-155.
26. Kuehl F.A., Ormond R.E., A. V.W.J. Occurrence of 3,4-dimethoxyphenylacetic acid in urine of normal and schizophrenic individuals. Nature. 211:1966;606-608.
27. J.W. Langston, Current theories on the cause of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, Special Suppl. (1989) 13-17.
28. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
29. Lyden A., Bondesson V., Larsson B.S. Melanin affinity of 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine, an inducer of chronic Parkinsonism in humans. Acta Pharmacol. Scand. 53:1983;429-432.
30. Markey S.P., Johannsen J.N., Chiueh C.C., Burns R.S., Herkenhan M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464.
31. Martin W.E., Young W.I., Anderson V.E. Parkinson's disease, a genetic study. Brain. 96:1973;495-506.
32. Maruyama W., Abe T., Tohgi H., Dostert P., Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann. Neurol. 40:1996;119-122.
33. Matsubara K., Collins M.A., Akane A., Ikebuchi J., Neafsey E.J., Kagawa M., Shiono H. Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res. 610:1993;90-96.
34. McNaught K.S.P., Thull U., Carrupt P.A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 5:1996;265-274.
35. McNaught K.S.P., Thull U., Carrupt P.A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. Pharmacol. 50:1995;1903-1911.
36. McNaught K.S.P., Thull U., Carrupt P.A., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. Biochem. Pharmacol. 51:1996;1503-1511.
37. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163:1989;1450-1455.
38. Mizuno Y., Satoh T., Sone N. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143:1987;294-299.
39. Mizuno Y., Sone N., Saitoh T. Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143:1987;971-976.
40. +) against mitochondria of mouse brain. J. Neurol. Sci. 86:1988;97-110.
41. Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I. J. Neurochem. 66:1996;1174-1181.
42. Naoi M., Maruyama W., Dostert P., Hashizume Y., Nakahara D., Takahashi T., Ota M. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 709:1996;285-295.
43. +) destroys cultured mesencephalic dopamine neurons. Biog. Amines. 8:1991;61-67.
44. Nishimura T., Gjessing L.G. Failure to detect 3,4-dimethoxyphenylethylamine and bufotenine in the urine from a case of periodic catatonia. Nature. 4987:1965;963-964.
45. Niwa T., Takeda N., Yoshizumi H., Tatematsu A., Yoshida M., Dostert P., Naoi M., Nagatsu T. Presence of 2-methyl-6,7-dehydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dehydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun. 177:1991;603-609.
46. Ohta S., Kohno M., Makino Y., Tachikawa O., HIrose M. Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed. Res. 8:1987;453-456.
47. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, 1982.
48. Perry T.L., Hansen S., Macintyre L. Failure to detect 3,4-dimethoxyphenylethylamine in the urine of schizophrenics. Nature. 4931:1964;519-520.
49. Ramsay R.R., Salach J.I., Dadgar J., Singer T.P. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135:1986;269-275.
50. Rinne U.K., Sonninen V. Urinary excretion of 3,4-dimethoxyphenylethylamine in Parkinson's disease. Nature. 216:1967;489.
51. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
52. Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1:1989;1269.
53. Schwarcz R., Whetsell W.O.J., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing in rat brain. Science. 219:1983;316-318.
54. Sirinathsinghji D.J.S. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway. I. Behavioral, neurochemical and histological characterization of the lesion Neuroscience. 27:1988;117-128.
55. Snyder S.H., D'Amato R.J. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology. 36:1986;250-258.
56. Sonsalla P.K., Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129:1986;339-345.
57. Steranka L.R., Polite L.N., Perry K.W., Fuller R.W. Dopamine depletion in rat brain by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Res. Commun. Subst. Abuse. 4:1983;315-323.
58. Suzuki K., Mizuno Y., Yamauchi Y., Nagatsu T., Mitsuo Y. Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain. J. Neurol. Sci. 109:1992;219-223.
59. Takesada M., Kakimoto Y., Sano I., Kaneko Z. 3,4-Dimethoxyphenylethylamine and other amines in the urine of schizophrenic patients. Nature. 4889:1963;203-204.
60. Whilhelmsen K.C., Wszolek Z. Is there a genetic susceptibility to idiopathic parkinsonism? Parkinsonism Related Disord. 1:1995;73-84.
61. Yoshida M., Niwa T., Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci. Lett. 119:1990;109-113.
62. Youdim M.B.H., Shatter D.B., Riederer P. Is Parkinson's disease a progressive of substantia nigra resulting in iron and melanin induced? Acta Neurol. Scand. 126:1989;47-54.